BioAge: $170 Million Raised To Accelerate Development Of Metabolic Disease Therapeutics
By Amit Chowdhry ● Feb 13, 2024
BioAge Labs - a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging - announced the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments. New investors - including Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, and Amgen Ventures - also participated in the round along with existing investors including Andreessen Horowitz (a16z) Bio + Health.